Public Listing

This page is intended to provide reference information on AbbVie UK medicines for UK members of the public only.

Reference Information for AbbVie UK Medicines

In the list below, you can access links to the Electronic Medicines Compendium (eMC), an external resource which provides information about medicines available in the UK.

HUMIRA® (adalimumab)

HUMIRA® (adalimumab) Patient Information Leaflet

HUMIRA® (adalimumab) Summary of Product Characteristics

SKYRIZI™▼ (risankizumab)

SKYRIZI™ (risankizumab) Patient Information Leaflet

SKYRIZI™ (risankizumab) Summary of Product Characteristics

RINVOQ® ▼ (upadacitinib)

RINVOQ® (upadacitinib) Patient Information Leaflet

RINVOQ® (upadacitinib) Summary of Product Characteristics

VENCLYXTO® ▼(venetoclax)

VENCLYXTO® (venetoclax) Patient Information Leaflet

VENCLYXTO® (venetoclax) Summary of Product Characteristics

DUODOPA® (levodopa/carbidopa intestinal gel) Patient Information Leaflet

DUODOPA® (levodopa/carbidopa intestinal gel) Summary of Product Characteristics

BOTOX® (botulinum toxin type A)

BOTOX® (botulinum toxin type A) Patient Information Leaflet

BOTOX® (botulinum toxin type A) Summary of Product Characteristics

Reporting of side effects:

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk. By reporting side effects you can help provide more information on the safety of these medicines.

For medicines with black triangle:

▼ means the medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects.

AbbVie Ltd
AbbVie House
Vanwall Business Park
Vanwall Road
Maidenhead
Berkshire
SL6 4UB
UK Telephone: 01628 561090

UK-ABBV-230119

Date of preparation: March 2023